IL1B and atherosclerosis: As the CANTOS and COLCOT trials generated promising evidence for the anti-atherogenic effects of IL-1β antibodies and colchicine, the inflammasome has amassed attention as the major driving factor of IL-1β-driven inflammation in atherosclerosis.